Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Return on Capital Employed data on record, last reported at 32.19% in Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 1151.0% to 32.19% in Q1 2026 year-over-year; TTM through Mar 2026 was 32.19%, a 1151.0% increase, with the full-year FY2025 number at 39.49%, up 1463.0% from a year prior.
  • Return on Capital Employed reached 32.19% in Q1 2026 per IKT's latest filing, up from 42.57% in the prior quarter.
  • Over the last five years, Return on Capital Employed for IKT hit a ceiling of 32.19% in Q1 2026 and a floor of 1184.15% in Q3 2024.
  • A 5-year average of 173.62% and a median of 76.21% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: plummeted -106890bps in 2024, then soared 111821bps in 2025.
  • Tracing IKT's Return on Capital Employed over 5 years: stood at 78.6% in 2022, then tumbled by -100bps to 157.5% in 2023, then skyrocketed by 62bps to 59.87% in 2024, then grew by 29bps to 42.57% in 2025, then increased by 24bps to 32.19% in 2026.
  • Business Quant data shows Return on Capital Employed for IKT at 32.19% in Q1 2026, 42.57% in Q4 2025, and 65.95% in Q3 2025.